A research team led by Minyoung Lee and Sunggyu Park of The Korea Institute of Materials Science (KIMS) Bio & Health ...
Breakthrough research led by scientists in Manchester has identified a new drug combination that could improve outcomes for ...
A common mutation in the KRAS gene is associated with improved overall survival in pancreatic ductal adenocarcinoma (PDAC) compared with other variants, in part because the mutation appears to lead to ...
An investigational targeted therapy designed to block one of the most common genetic drivers of pancreatic cancer has shown ...
The ultra-sensitive test can find hidden signs of pancreatic cancer by looking for a key KRAS genetic mutation missed by ...
ScienceAlert on MSN
Experimental Drug Stops 90% of Pancreatic Cancer Cell Spread in Lab Tests
The pancreas is in the upper part of the abdomen. (Sebastian Kaulitzki/Science Photo Library/Getty Images) Pancreatic ductal ...
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted ...
The Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell ...
Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval. According to the National Cancer ...
Share on Pinterest New research shows certain KRAS mutations in pancreatic cancer may improve survival rates compared to other mutations. William Taufic/Getty Images In 2020, more than 495,000 adults ...
Nivolumab (Nivo) plus ipilimumab (Ipi) 6-month treatment versus continuation in patients with advanced non-small-cell-lung cancer (aNSCLC): 3-year results of the IFCT-1701 DICIPLE phase 3 trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results